Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?

JAMA

Volumn 286, Issue 15, 2001, Pages 1886-1892

  Attaran, Amir ^a   Gillespie White, Lee ^b  

^a HARVARD UNIVERSITY   (United States)

^b McKenna Long and Aldridge LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; CORRELATION FUNCTION; DRUG COST; DRUG INDUSTRY; DRUG USE; HEALTH CARE POLICY; HUMAN; PATENT; POVERTY; PRIORITY JOURNAL;

EID: 0035904286     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.15.1886     Document Type: Article

References (45)

1. Access to essential drugs in poor countries: A lost battle?
2. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
3. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals
4. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (START I)
5. AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients
6. Viral resistance results from the international, multicenter, randomized, placebo-controlled, 48-week study of hydroxyurea or placebo combined with efavirenz, didanosine and stavudine in treatment-naive and -experienced patients
7. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting
8. The VIRGO study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
9. Adverse reaction: AIDS gaffes in Africa come back to haunt drug industry at home
10. Patent protection of medicines in Kenya and Uganda
11. The conflicts between parallel trade and product access and innovation: The case of pharmaceuticals
12. Consumption and trade in off-patented medicines
13. AIDS drug battle deepens in Africa
14. Tuberculosis drug issues: Prices, fixed dose combination products and second line drugs
15. Responding to market failures in tuberculosis control
16. UN conference endorses battle plan for HIV/AIDS
17. Respective contributions of the public and private sector in the development of new drugs: Implications for drug access in the developing world
18. Intellectual property rights and the use of compulsory licenses: Options for the developing countries
19. Compulsory licensing provisions under the TRIPS agreement: Balancing pills and patents
20. Defining and refining international donor support for combating the AIDS pandemic
21. Consensus statement on antiretroviral treatment for AIDS in poor countries by individual members of the faculty of Harvard University
22. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
23. Human rights and biomedical research funding for the developing world: Discovering state obligations under the right to health